One of Nanologica’s patent applications has today become public. Through the patent, Nanologica is seeking to strengthen and expand its technology platform by adding inhalation, among other, as administration route. The technology is in an early phase and is believed to be able to overcome some of the challenges surrounding administration of drugs through inhalation. ”Inhalation interests us for several reasons. We see great potential in the reformulation of approved substances for finding more effective
Nanologica AB (publ) has today entered into a five-year distribution agreement with Yunbo Technology (Beijing) Co. for the Chinese market. The agreement gives Yunbo exclusivity according to predetermined sales volumes, which increase yearly. In connection with the signing of the agreement Yunbo also made an order of products to a value of 2 MSEK for delivery during the fourth quarter of 2018. Through the agreement Yunbo will market and resell Nanologica’s chromatographical products in China.
Vicore Pharma AB (publ) will decide on an acquisition of INIM Pharma AB, where Nanologica AB is a minor shareholder, in an Extraordinary General Meeting. If the acquisition is carried out Nanologica will be paid a licence fee of 2 MSEK and a project based on Nanologica’s technical platform, licensed by INIM Pharma, will start. Vicore’s main focus is pulmonary diseases where the company’s drug candidate, C21, is facing a clinical phase II study within
Nanologica has signed a three-year supply agreement with Chinese SinoUnison who focuses on analytical services within food control. Nanologica will supply chromatography columns and SinoUnison will also develop new methods based on Nanologica’s products. The food control industry is growing rapidly in China and the need for adequate analytical equipment in terms of chromatography columns is increasing dramatically. Nanologica’s chromatography columns meet the highly set quality standards of SinoUnison. “We are happy to establish a
Nanologica licenses part of its technology platform to INIM Pharma AB, a company set up by HealthCap. The new company is focused on certain therapeutic areas. Nanologica will obtain a minor ownership in the company, receive a fee of 2 MSEK when the company has been financed, and additional 1 MSEK for every project that goes into clinical trial, as well as remuneration for development work carried out for the new company. The license agreement